INOMAX™ (nitric oxide)
Product Specific Indications
INOmax™, in conjunction with ventilatory support and other appropriate agents, is indicated:
- for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.
- to selectively decrease pulmonary arterial pressure in patients with perioperative pulmonary hypertension conjunction with heart surgery.
The Therapeutic Goods Administration (TGA) specifies that INOMAX must be delivered through an approved nitric oxide delivery system meeting specific quality and safety criteria. For full details refer to INOMAX™ Product Information.
|INOmax™ PI||335.21 KB|
|INOmax™ CMI||118.36 KB|
|INOmax™ MSDS||196.78 KB|